Metacam Dosage for Dogs Calculator

Meloxicam is an enolic acid of the oxicam class, a non-steroidal anti-inflammatory that preferentially inhibits cyclooxygenase-2 over cyclooxygenase-1. COX-2 is induced at sites of injury and drives the prostaglandins responsible for inflammatory pain and peripheral sensitisation, while COX-1 maintains gastric mucosal blood flow and platelet aggregation, so a COX-2-preferential drug delivers analgesia at somewhat lower gastrointestinal cost than older non-selective NSAIDs. Canine dosing is 0.2 mg/kg on day one followed by 0.1 mg/kg once daily. The doubled first dose exists because meloxicam has a long elimination half-life in dogs, commonly reported near 24 hours, and loading fills the volume of distribution in one step instead of waiting three to five half-lives for steady state. Volume is the practical output: dose in milligrams divided by concentration. Veterinary oral suspensions are supplied at 1.5 mg/mL for dogs and 0.5 mg/mL for small dogs, with the injectable at 5 mg/mL, so a 25 kg dog needs about 1.67 mL of the 1.5 mg/mL product daily. Precision matters most at the small end, where a 4 kg dog needs only 0.27 mL, which is exactly why the dilute suspension exists. The limits are real. NSAIDs remove prostaglandin support for renal perfusion, so hypotension, dehydration, anaesthesia, or concurrent ACE inhibitors and diuretics raise the risk of acute kidney injury. Meloxicam must never be combined with corticosteroids or a second NSAID, and switching between NSAIDs conventionally requires a washout of several days.

The pharmacological basis was laid by John Vane, whose 1971 work showed that aspirin-like drugs act by blocking prostaglandin synthesis, a finding recognised with a share of the 1982 Nobel Prize in Physiology or Medicine. The discovery in the early 1990s that the enzyme exists as two isoforms, a constitutive COX-1 and an inducible COX-2, reframed NSAID design around sparing the housekeeping isoform. Meloxicam was developed by the German pharmaceutical firm Boehringer Ingelheim and reached human medicine in Europe during the mid-1990s under the name Mobic. Veterinary registration followed. Metacam was licensed for dogs in Europe before the United States, where FDA approval of the injectable and then the oral suspension for canine osteoarthritis came in the early 2000s, making it one of the first NSAIDs cleared specifically for long-term use in dogs rather than short post-operative courses. That mattered because canine pain control had previously leaned on off-label human drugs with poor canine safety margins. Later labelling changes reflect accumulated pharmacovigilance: the product now carries a prominent warning against repeated dosing in cats following reports of acute renal failure, and veterinary practice has converged on baseline and periodic bloodwork for dogs maintained on the drug.